Free Trial
NASDAQ:XLO

Xilio Therapeutics (XLO) Stock Price, News & Analysis

$0.82
0.00 (0.00%)
(As of 09/13/2024 08:54 PM ET)
Today's Range
$0.79
$0.87
50-Day Range
$0.74
$1.02
52-Week Range
$0.49
$2.89
Volume
273,600 shs
Average Volume
593,907 shs
Market Capitalization
$30.27 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Xilio Therapeutics MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
0.13% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.28mentions of Xilio Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.26) to ($0.58) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.41 out of 5 stars

Medical Sector

737th out of 927 stocks

Biotechnology Industry

11th out of 19 stocks

XLO stock logo

About Xilio Therapeutics Stock (NASDAQ:XLO)

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.

XLO Stock Price History

XLO Stock News Headlines

Short Interest in Xilio Therapeutics, Inc. (NASDAQ:XLO) Drops By 72.1%
War on Elon Escalates…
Elon Musk just built a supercomputer in Memphis, Tennessee. It took him only 122 days. Dubbed “Colossus,” this supercomputer aims to become the most powerful AI training system in the world. Housed in a 785,000 sq. ft facility in Memphis, Colossus will soon require 150 megawatts of electricity per day. That’s about equal to the amount of energy needed to power 100,000 homes per year.
War on Elon Escalates…
Elon Musk just built a supercomputer in Memphis, Tennessee. It took him only 122 days. Dubbed “Colossus,” this supercomputer aims to become the most powerful AI training system in the world. Housed in a 785,000 sq. ft facility in Memphis, Colossus will soon require 150 megawatts of electricity per day. That’s about equal to the amount of energy needed to power 100,000 homes per year.
Why Is Xilio Therapeutics (XLO) Stock up 168% Today?
See More Headlines
Receive XLO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Xilio Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/08/2024
Today
9/15/2024
Next Earnings (Estimated)
11/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:XLO
Fax
N/A
Employees
73
Year Founded
N/A

Profitability

Net Income
$-76,400,000.00
Pretax Margin
-2,780.27%

Debt

Sales & Book Value

Annual Sales
$2.36 million
Book Value
$1.34 per share

Miscellaneous

Free Float
34,993,000
Market Cap
$30.27 million
Optionable
Not Optionable
Beta
-0.10
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Dr. Rene Russo BCPS (Age 49)
    Pharm.D., President, CEO & Director
    Comp: $875.13k
  • Mr. Christopher Frankenfield (Age 42)
    Chief Operating Officer
    Comp: $704.85k
  • Dr. Katarina Luptakova M.D. (Age 48)
    Chief Medical Officer
    Comp: $591.92k
  • Mr. Kevin M. Brennan (Age 54)
    Senior VP of Finance & Accounting
  • Dr. Uli Bialucha Ph.D.
    Chief Scientific Officer
  • Dr. Scott Coleman Ph.D.
    Chief Development Officer

XLO Stock Analysis - Frequently Asked Questions

How have XLO shares performed this year?

Xilio Therapeutics' stock was trading at $0.55 at the beginning of 2024. Since then, XLO shares have increased by 49.1% and is now trading at $0.82.
View the best growth stocks for 2024 here
.

How were Xilio Therapeutics' earnings last quarter?

Xilio Therapeutics, Inc. (NASDAQ:XLO) posted its quarterly earnings results on Thursday, August, 8th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by $0.01. The firm had revenue of $2.36 million for the quarter, compared to analysts' expectations of $30 million.

When did Xilio Therapeutics IPO?

Xilio Therapeutics (XLO) raised $125 million in an initial public offering (IPO) on Friday, October 22nd 2021. The company issued 7,353,000 shares at a price of $16.00-$18.00 per share.

Who are Xilio Therapeutics' major shareholders?

Top institutional investors of Xilio Therapeutics include Renaissance Technologies LLC (0.80%) and XTX Topco Ltd (0.08%). Insiders that own company stock include Gilead Sciences, Inc, Venture Fund Xi LP Atlas, Bain Capital Life Sciences Inv and Rock Springs Capital Managemen.
View institutional ownership trends
.

How do I buy shares of Xilio Therapeutics?

Shares of XLO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:XLO) was last updated on 9/16/2024 by MarketBeat.com Staff

From Our Partners